Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pagoclone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 0.30 mg pagoclone BID |
| 2 | EXPERIMENTAL | 0.60 mg pagoclone BID |
| 3 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| pagoclone | DRUG | 0.30 mg BID, 0.60 mg BID |
| placebo | OTHER | placebo |
Inclusion Criteria: * Male and females age 18 to 80 years presenting with a history of stuttering with onset prior to age 8 years old. * Stuttering severity must be notable for \> 3 syllables stuttered on a reading and cenversational task at scereening and with at least 2% contributed individually ...
Pagoclone is an investigational small molecule being studied for the treatment of stuttering in adults. It is a Phase 2 investigational drug and is not approved by the FDA. Its development is being conducted by Teva Pharmaceutical Industries Limited.
Pagoclone is being developed by Teva Pharmaceutical Industries Limited, which is listed on the stock exchange under the ticker TEVA. The company is conducting clinical research to evaluate the drug's safety and efficacy for stuttering.
Pagoclone is in Phase 2 clinical development. A Phase 2 study has been completed to assess its efficacy and safety in adults with stuttering. The drug remains investigational and has not received regulatory approval.
Pagoclone has been studied in a completed Phase 2 clinical trial with the identifier NCT00830154. This trial was a randomized, double-blind, placebo-controlled study that enrolled 321 adults with stuttering in the United States.
Pagoclone is a distinct investigational drug and is not known to be the same as any other marketed medication. It is being evaluated specifically for stuttering and has no alternative names listed in its clinical development program.